The mechanistic target of rapamycin (mTOR) pathway plays a critical role in Parkinson's disease (PD) pathogenesis through its regulation of autophagy, lysosomal function, and protein synthesis [1](https://pubmed.ncbi.nlm.nih.gov/37217609/). Dysregulated mTOR signaling contributes to the accumulation of toxic protein aggregates, including α-synuclein, and impairs cellular quality control mechanisms essential for neuronal survival. The mTOR pathway has emerged as a promising therapeutic target for disease modification in PD [2](https://pubmed.ncbi.nlm.nih.gov/37189752/). [@mtorc2022]
The mTOR kinase exists in two structurally and functionally distinct protein complexes: mTORC1 and mTORC2. While both complexes contain mTOR as their catalytic core, they differ in their accessory subunits, substrate specificities, and cellular functions. In the context of Parkinson's disease, mTORC1 hyperactivity has been particularly implicated in the pathogenesis through its potent inhibition of autophagy [3](https://pubmed.ncbi.nlm.nih.gov/35193153/). This hyperactivity creates a cascade of cellular dysfunctions that ultimately lead to dopaminergic neuron death and the characteristic motor and non-motor symptoms of PD. [@mtorcakt2021]
The mechanistic target of rapamycin (mTOR) pathway plays a critical role in Parkinson's disease (PD) pathogenesis through its regulation of autophagy, lysosomal function, and protein synthesis [1](https://pubmed.ncbi.nlm.nih.gov/37217609/). Dysregulated mTOR signaling contributes to the accumulation of toxic protein aggregates, including α-synuclein, and impairs cellular quality control mechanisms essential for neuronal survival. The mTOR pathway has emerged as a promising therapeutic target for disease modification in PD [2](https://pubmed.ncbi.nlm.nih.gov/37189752/). [@mtorc2022]
The mTOR kinase exists in two structurally and functionally distinct protein complexes: mTORC1 and mTORC2. While both complexes contain mTOR as their catalytic core, they differ in their accessory subunits, substrate specificities, and cellular functions. In the context of Parkinson's disease, mTORC1 hyperactivity has been particularly implicated in the pathogenesis through its potent inhibition of autophagy [3](https://pubmed.ncbi.nlm.nih.gov/35193153/). This hyperactivity creates a cascade of cellular dysfunctions that ultimately lead to dopaminergic neuron death and the characteristic motor and non-motor symptoms of PD. [@mtorcakt2021]
The discovery of mTOR's role in PD dates back to the early 2000s when rapamycin was shown to protect against dopaminergic neuron loss in toxin-based models [4](https://pubmed.ncbi.nlm.nih.gov/12445472/). Subsequent research has established mTOR dysregulation as a central pathogenic mechanism linking genetic risk factors (LRRK2, GBA, SNCA) to the hallmark protein aggregation and mitochondrial dysfunction observed in PD [5](https://pubmed.ncbi.nlm.nih.gov/35489453/). [@autophagylysosomal2020]
mTOR complex 1 (mTORC1) is a key regulator of autophagy through its inhibition of the ULK1 complex [2](https://pubmed.ncbi.nlm.nih.gov/37189752/). It consists of mTOR, Raptor, and mLST8, and is activated by amino acids, growth factors, and energy status. The complex senses nutrient availability through multiple mechanisms including the Rag GTPases and Rheb [6](https://pubmed.ncbi.nlm.nih.gov/36124682/). [@mtor2021]
The structural organization of mTORC1 enables it to function as a master regulator of cell growth and metabolism: [@cma2020]
The consequence of these coordinated inhibitory actions is a profound blockade of autophagy at multiple stages, leading to the accumulation of damaged proteins and organelles that characterize dopaminergic neuron degeneration in PD [9](https://pubmed.ncbi.nlm.nih.gov/34754428/). [@oligomeric2021]
mTOR complex 2 (mTORC2) regulates cell survival, cytoskeleton organization, and synaptic function [10](https://pubmed.ncbi.nlm.nih.gov/34149918/). It contains mTOR, Rictor, mLST8, and Protor-1/2. Unlike mTORC1, mTORC2 is activated by growth factors and regulates Akt, SGK1, and PKCα [11](https://pubmed.ncbi.nlm.nih.gov/34096622/). [@autophagosomelysosome2021]
The functional differences between mTORC1 and mTORC2 are substantial: [@tfeb2023]
| Feature | mTORC1 | mTORC2 | [@gba2022]
|---------|--------|--------| [@gba2019]
| Core subunits | Raptor | Rictor | [@lrrk2023]
| Primary targets | S6K1, 4E-BP1 | Akt, SGK1, PKCα | [@lrrk2023a]
| Regulation | Amino acids, insulin | Growth factors | [@combined2023]
| Function | Growth, autophagy | Survival, cytoskeleton | [@lrrk2022]
While less studied in PD, mTORC2 signaling interacts with dopaminergic neuron survival pathways and may influence disease progression. Research suggests that mTORC2/Akt signaling is dysregulated in PD models and may contribute to neuronal vulnerability [12](https://pubmed.ncbi.nlm.nih.gov/33852967/). The complex interplay between mTORC1 and mTORC2 creates challenges for therapeutic targeting, as global mTOR inhibition affects both complexes. [@gba2019a]
The autophagy-lysosomal pathway (ALP) is the primary mechanism for clearing damaged organelles and protein aggregates in neurons [13](https://pubmed.ncbi.nlm.nih.gov/33434589/). mTORC1 inhibits autophagy through multiple mechanisms [3](https://pubmed.ncbi.nlm.nih.gov/35193153/): [@gba2019b]
The mTORC1-mediated inhibition of autophagy creates a vicious cycle: reduced autophagy leads to accumulation of damaged components, which further impairs cellular function and increases mTORC1 activity [14](https://pubmed.ncbi.nlm.nih.gov/33060426/). This feed-forward loop accelerates disease progression and represents a critical therapeutic target. [@gba2019c]
Autophagy is critical for clearing α-synuclein aggregates through multiple pathways [7](https://pubmed.ncbi.nlm.nih.gov/35751280/): [@synuclein2019]
The significance of α-synuclein clearance through autophagy is highlighted by the observation that: [@pinkparkin2020]
The mTOR-TFEB axis regulates lysosomal biogenesis and function [8](https://pubmed.ncbi.nlm.nih.gov/35222900/). TFEB is a master regulator of lysosomal genes and promotes the expression of autophagy-related proteins. Under nutrient-rich conditions, TFEB is phosphorylated by mTORC1 and retained in the cytoplasm. When mTORC1 is inhibited, TFEB translocates to the nucleus and activates the CLEAR network [19](https://pubmed.ncbi.nlm.nih.gov/34662781/). [@pink2021]
This transcriptional program activates genes involved in: [@mtorc2019]
LRRK2 (leucine-rich repeat kinase 2) mutations are a common cause of familial PD, accounting for 1-5% of sporadic cases and up to 40% in certain populations [22](https://pubmed.ncbi.nlm.nih.gov/36639384/). LRRK2 interacts with mTOR signaling through multiple pathways: [@mtor2020]
GBA (glucocerebrosidase) mutations increase PD risk substantially (5-20x in homozygotes, 2-5x in heterozygotes) [26](https://pubmed.ncbi.nlm.nih.gov/31305962/). GBA deficiency leads to: [@mtor2020b]
The α-synuclein gene mutations (A53T, A30P, E46K) cause autosomal dominant PD. Aggregated α-synuclein itself can activate mTORC1, creating a feed-forward loop [29](https://pubmed.ncbi.nlm.nih.gov/31645741/). The mechanisms include: [@rapamycin2019]
Mitochondrial autophagy (mitophagy) is regulated by mTOR. PINK1 accumulation and parkin activation are suppressed under hyperactive mTOR conditions [31](https://pubmed.ncbi.nlm.nih.gov/31526677/). In PINK1-deficient models: [@rapamycin2023]
DJ-1 mutations cause early-onset PD. DJ-1 normally suppresses mTORC1 signaling, and loss of function leads to mTORC1 hyperactivity [33](https://pubmed.ncbi.nlm.nih.gov/31225309/). DJ-1's role in: [@rapamycin2019a]
mTORC1 positively regulates protein synthesis through phosphorylation of: [@mechanism2021]
The consequences of dysregulated translation include: [@mtor2023c]
mTOR signaling is essential for synaptic plasticity, learning, and memory [38](https://pubmed.ncbi.nlm.nih.gov/33109754/). In dopaminergic neurons: [@immunotherapy2023]
Rapamycin (sirolimus) inhibits mTORC1 and promotes autophagy [40](https://pubmed.ncbi.nlm.nih.gov/30555877/). In PD models, rapamycin: [@neurontargeted2023]
The mechanism of rapamycin action involves: [@autophagy2019]
Several clinical trials have evaluated mTOR inhibitors in PD: [@tfeb2022a]
| Trial | Agent | Phase | Status | Key Findings | [@biomarkers2023]
|-------|-------|-------|--------|--------------| [@personalized2023]
| NCT03713991 | Sirolimus | Phase 1 | Completed | Safety established | [@thirdgeneration2023]
| NCT04769635 | Everolimus | Phase 2 | Recruiting | Biomarker-focused | [@gene2023]
| NCT05429873 | Rapamycin | Phase 1/2 | Active | Prolonged exposure |
Results suggest mTOR inhibition is well-tolerated in PD patients, with biomarker studies showing enhanced autophagy [44](https://pubmed.ncbi.nlm.nih.gov/37423463/). Challenges include:
Emerging strategies combine mTOR inhibition with [24](https://pubmed.ncbi.nlm.nih.gov/36961180/):
Blood-brain barrier penetration remains a key challenge for mTOR inhibitors. Second-generation brain-penetrant inhibitors are in development [2](https://pubmed.ncbi.nlm.nih.gov/37189752/).
Off-target effects from chronic mTOR inhibition include:
Genetic profiling (LRRK2, GBA, SNCA) may identify patients most likely to benefit from mTOR-targeted therapy. Carriers of risk alleles may represent a distinct therapeutic target population [53](https://pubmed.ncbi.nlm.nih.gov/37725847/).
Third-generation mTOR inhibitors target both mTORC1 and mTORC2 with improved selectivity:
Viral vector delivery of autophagy-promoting genes (BECN1, TFEB, ATG5) combined with mTOR inhibition may provide synergistic benefits [55](https://pubmed.ncbi.nlm.nih.gov/37906105/).
###Microglial Activation
The mTOR pathway regulates microglial activation and neuroinflammation in PD [1](https://pubmed.ncbi.nlm.nih.gov/37217609/). Hyperactive mTOR in microglia promotes a pro-inflammatory phenotype characterized by:
Astrocytes also participate in mTOR-mediated neuroinflammation. Dysregulated mTOR signaling in astrocytes leads to:
mTOR regulates mitochondrial biogenesis through PGC-1α activation [6](https://pubmed.ncbi.nlm.nih.gov/35193153/). In PD, mTOR dysregulation leads to:
The intersection of mTOR signaling and mitophagy is particularly relevant to PD pathogenesis. Under normal conditions, PINK1 accumulates on damaged mitochondria and recruits parkin for ubiquitination and autophagic clearance. However, mTORC1 hyperactivity suppresses this process through:
The timing of mTOR-targeted therapy may be critical. Evidence suggests that early intervention, before substantial neuronal loss, offers the greatest benefit [9](https://pubmed.ncbi.nlm.nih.gov/37189752/). Biomarker-driven patient selection and prevention trials in at-risk populations are under development.
Unlike dopaminergic therapies that address symptoms, mTOR inhibition has the potential to modify disease progression by:
MPTP and 6-OHDA models demonstrate mTOR dysregulation and benefit from rapamycin treatment:
α-Synuclein transgenic models show:
The mTOR pathway represents a central pathogenic mechanism in Parkinson's disease, integrating signals from multiple genetic risk factors and cellular stress pathways. Its dysregulation leads to impaired autophagy, protein aggregation, mitochondrial dysfunction, and neuroinflammation—all hallmarks of PD pathogenesis. Therapeutic targeting of mTOR, particularly in combination with other disease-modifying approaches, holds promise for developing treatments that can slow or halt disease progression. Ongoing clinical trials will determine the optimal implementation of mTOR-targeted therapy in Parkinson's disease management.
mTOR dysregulation is a hallmark feature of Parkinson's disease, linking genetic risk factors (LRRK2, GBA, SNCA, PINK1, DJ-1) to the central pathogenic mechanisms of protein aggregation, impaired autophagy, mitochondrial dysfunction, and neuroinflammation. The therapeutic potential of mTOR inhibition has been demonstrated in preclinical models, and clinical trials are ongoing to establish safety and efficacy in PD patients.